Have money to deploy today? Put it in pharma funds, says Sandeep Tandon

Sandeep Tandon of Quant Mutual Fund believes India is decoupling from developed economies, particularly within the Asia-centric emerging market. He highlights the pharma sector as a key beneficiary in the current economic climate, dismissing concerns about significant US tariffs on Indian generics. Tandon advocates investing in pharma funds, viewing it as a straightforward and promising […]

Valuation correction creating stock-specific opportunities, not sectoral bets: Ashwini Agarwal

Ashwini Agarwal of Demeter Advisors suggests focusing on individual stocks rather than broad sectors. Domestic healthcare and consumption names appear promising. Textile exports might offer buying opportunities if tariffs impact them negatively. India’s manufacturing cost advantage remains strong long-term. Agarwal is currently tracking companies improving their earnings profile. Companies recovering from a downcycle are also […]

Lupin shares jump 5% after strong Q1 results. Should you accumulate more?

Lupin shares jumped 5% after reporting a 52% YoY rise in Q1 FY26 net profit to Rs 1,221 crore, driven by strong US and India sales. Revenue rose to Rs 6,164 crore. While Choice Broking upgraded the stock to ‘Buy’ with a Rs 2,375 target, Motilal Oswal maintained a ‘Neutral’ view citing limited upside despite […]

Stay invested, look beyond the dip: Ashwini Agarwal’s advice as markets face headwinds

Ashwini Agarwal of Demeter Advisors advises Indian investors to ignore short-term market noise, including potential tariff impacts and IPO market activity. Despite current headwinds like weak earnings, he anticipates lower interest rates boosting domestic demand. Agarwal suggests a long-term view, highlighting opportunities in sectors like non-banking financial services, particularly MFIs, where valuations are attractive.

Bajaj Auto shares slip 4% after Q1 results. Should you buy, sell or hold?

Bajaj Auto shares fell nearly 4% despite a 14% YoY rise in Q1FY26 PAT to ₹2,210 crore. Revenue grew 10% to ₹13,133 crore, driven by strong export and premium segment sales. EBITDA stood at ₹2,500 crore with a 19.7% margin, down QoQ due to lower dollar realisations, partially offset by better product mix.